(Q35036558)

5 August 2017

PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium (English)

1 reference

5 August 2017

0 references

5

Vincent Ravery

1 reference

5 August 2017

3

Alexandre Zlotta

0 references

author name string

Bob Djavan

1

1 reference

5 August 2017

Judd W Moul

2

1 reference

5 August 2017

Alexandre Zlotta

3

1 reference

5 August 2017

Mesut Remzi

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

5 August 2017

1 reference

5 August 2017

43

1 reference

5 August 2017

1

1 reference

5 August 2017

12-27

1 reference

5 August 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Serum Prostatic Antigen Measurement in Localized Prostatic Cancer: Correlation with Clinical Course

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Influence of digital rectal massage on urinary prostate-specific antigen: interest for the detection of local recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate Specific Antigen and Local Recurrence after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Correlation of pathologic findings with progression after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Five year follow-up after radical prostatectomy for localized prostate cancer--a study of the impact of different tumor variables on progression

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Predictive value of pathological features for progression after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Artificial neural network model to predict biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Serum prostate-specific antigen after post-prostatectomy radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Radical prostatectomy after radiotherapy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Salvage radical prostatectomy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Salvage Radical Prostatectomy for Radiorecurrent Adenocarcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Radical prostatectomy after definitive radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

The role of radical surgery in the management of radiation recurrent and large volume prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Salvage surgery for radiation failure in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Percutaneous cryoablation of the prostate: preliminary results after 95 procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

The efficacy and complications of salvage cryotherapy of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Salvage brachytherapy for localized prostate cancer after radiotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

125iodine reimplantation for locally progressive prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Estrogens in the Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent endocrine therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent endocrine therapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

A pilot study of intermittent androgen deprivation in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Antiandrogens as monotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Sequential androgen blockade: a biological study in the inhibition of prostatic growth

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900505-5

7 January 2021

10.1016/S0302-2838(02)00505-5

Identifiers

DOI

1 reference

5 August 2017

1 reference